CHICAGO, Dec. 10, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Novartis Reports Encouraging Data on Biosimilar Candidate
Novartis (NYSE:NVS-Free Report) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
The study (n=218) is being conducted to compare the efficacy and safety of the biosimilar version of Amgen's (Nasdaq:AMGN-Free Report) Neupogen (filgrastim).
Neupogen is approved for the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy.
Data from the study reported that the candidate showed similarity to Neupogen. The data also showed that repeated switching at each cycle between the investigational biosimilar and Neupogen had no impact on efficacy, safety or immunogenicity.
We remind investors that the FDA accepted Sandoz's application for the biosimilar version of Neupogen, which makes it the first company to have a filing accepted under the new U.S. biosimilar pathway created by the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Sandoz's application was supported by the results from the PIONEER study.
Biosimilars are the growth engine of Sandoz, generating double-digit sales in the third quarter driven by continued momentum in its three in-market products – Omnitrope (human growth hormone), Binocrit (epoetin alfa) and Zarzio (filgrastim).
Novartis also presented six-year results from the randomized phase III study, ENESTnd, on Tasigna at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco. The study showed continued superiority of Tasigna over Glivec in achieving higher rates of early, deep and sustained molecular responses in patients with newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
Moreover, Novartis announced data on oncology drug Jakavi at the ASH from the JUMP study, which showed that 69% myelofibrosis patients achieved above 50% reduction in spleen size from baseline when treated with Jakavi. These patients also experienced a clinically meaningful improvement in the myelofibrosis symptom score.
We remind investors that Novartis has a collaborative agreement with Incyte Corp. (Nasdaq:INCY-Free Report) for the commercialization of Jakavi in the ex-U.S. markets.
Jakavi (known as Jakafi in the U.S.) recently gained FDA approval for the treatment of patients with polycythemia vera, who had an inadequate response or are intolerant to hydroxyurea.
We cautiously watch Novartis' efforts to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. Successful development and commercialization of its pipeline is important at this stage as Novartis faces generic competition for several of its key drugs such as Gleevec, Zometa and Diovan.
Novartis, a large-cap pharma, currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the health care sector may consider Allergan (NYSE:AGN-Free Report), carrying a Zacks Rank #1 (Strong Buy).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on NVS - FREE
Get the full Report on AMGN - FREE
Get the full Report on INCY - FREE
Get the full Report on AGN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-zacks-analyst-blog-highlights-novartis-amgen-incyte-and-allergan-300007693.html
SOURCE Zacks Investment Research, Inc.
Share this article